Research And Markets Research And Markets
0 CHECKOUT

Burns - Pipeline Review, H2 2015

  • ID: 3446803
  • September 2015
  • 102 pages
  • Global Markets Direct
1 of 3

Burns - Pipeline Review, H2 2015

Summary

The report ‘Burns - Pipeline Review, H2 2015’, provides an overview of the Burns’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Burns, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burns and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Burns Overview

Therapeutics Development

Pipeline Products for Burns - Overview

Pipeline Products for Burns - Comparative Analysis

Burns - Therapeutics under Development by Companies

Burns - Therapeutics under Investigation by Universities/Institutes

Burns - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Burns - Products under Development by Companies

Burns - Products under Investigation by Universities/Institutes

Burns - Companies Involved in Therapeutics Development

Adocia

AlgiPharma AS

Biogenomics Limited

Birken AG

CytoTools AG

Destiny Pharma Limited

HanAll Biopharma Co., Ltd.

Kuros Biosurgery AG

MediWound Ltd.

Novan, Inc.

Novartis AG

Pherecydes Pharma SA

Phosphagenics Limited

Se-cure Pharmaceuticals Ltd.

Stratatech Corporation

USV Limited

Vida Therapeutics Inc.

Xiber Science GmbH

Burns - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

albumin (human) (recombinant) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALLO-ASC - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Biochaperone PDGF-BB - Drug Profile

Product Description

Mechanism of Action

R&D Progress

bromelains - Drug Profile

Product Description

Mechanism of Action

R&D Progress

BVS-857 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug for Dermatology and Infectious Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

epidermal growth factor biosimilar - Drug Profile

Product Description

Mechanism of Action

R&D Progress

G-10 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HL-156FIB - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IMSP-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KUR-212 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MP-101 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OleogelS-10 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oligomer G for Wounds And Burns - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PEP-04 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PP-0121 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PP-1131 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SC-106 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Chronic Wounds and Burns - Drug Profile

Product Description

Mechanism of Action

R&D Progress

StrataGraft Skin Tissue - Drug Profile

Product Description

Mechanism of Action

R&D Progress

V-2248 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

XF-70 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Xib-1302 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Burns - Recent Pipeline Updates

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Featured News & Press Releases

Apr 29, 2015: Poster Presentation Highlighting NexoBrid Awarded Best-in-Category in Wound Care Practice at the American Burn Association 47th Annual Meeting

Apr 21, 2015: MediWound's NexoBrid Highlighted in Presentations at the 2015 American Burn Association 47th Annual Meeting

Apr 20, 2015: MediWound Initiates U.S. Phase 3 Trial With NexoBrid to Treat Severe Burns

Mar 23, 2015: MediWound's NexoBrid Highlighted in a Presentation at the International Conference on Minimally Invasive Medicine

Nov 03, 2014: MediWound Initiates Post-Marketing Study with NexoBrid to Treat Severe Burns in Pediatric Patients

Oct 07, 2014: MediWound's NexoBrid to be Featured at International Society for Burn Injuries 2014

Jul 16, 2014: MediWound Announces NexoBrid Marketing Approval From Israeli Ministry of Health

May 12, 2014: MediWound Completes Recruitment of Commercial Management Team in Europe

May 08, 2014: MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica

Sep 23, 2012: Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug - NexoBrid

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Burns, H2 2015

Number of Products under Development for Burns - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Burns - Pipeline by Adocia, H2 2015

Burns - Pipeline by AlgiPharma AS, H2 2015

Burns - Pipeline by Biogenomics Limited, H2 2015

Burns - Pipeline by Birken AG, H2 2015

Burns - Pipeline by CytoTools AG, H2 2015

Burns - Pipeline by Destiny Pharma Limited, H2 2015

Burns - Pipeline by HanAll Biopharma Co., Ltd., H2 2015

Burns - Pipeline by Kuros Biosurgery AG, H2 2015

Burns - Pipeline by MediWound Ltd., H2 2015

Burns - Pipeline by Novan, Inc., H2 2015

Burns - Pipeline by Novartis AG, H2 2015

Burns - Pipeline by Pherecydes Pharma SA, H2 2015

Burns - Pipeline by Phosphagenics Limited, H2 2015

Burns - Pipeline by Se-cure Pharmaceuticals Ltd., H2 2015

Burns - Pipeline by Stratatech Corporation, H2 2015

Burns - Pipeline by USV Limited, H2 2015

Burns - Pipeline by Vida Therapeutics Inc., H2 2015

Burns - Pipeline by Xiber Science GmbH, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Burns Therapeutics - Recent Pipeline Updates, H2 2015

Burns - Dormant Projects, H2 2015

Burns - Dormant Projects (Contd..1), H2 2015

Burns - Dormant Projects (Contd..2), H2 2015

Burns - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Burns, H2 2015

Number of Products under Development for Burns - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Cache